Drug Database
LY

lyophilized hepatitis-B human immunoglobulin

✓ Approved

Tonrol Bio-Pharmaceutical · 多克隆抗体 · 多克隆抗体

什么是 lyophilized hepatitis-B human immunoglobulin?

lyophilized hepatitis-B human immunoglobulin 是一种多克隆抗体,由Tonrol Bio-Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司Tonrol Bio-Pharmaceutical
药物类别多克隆抗体, 疫苗, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

lyophilized hepatitis-B human immunoglobulin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsHepatitis B✓ Approved

相关研究文献

PubMedEmerging infectious diseases2026-11-19

Rat Hepatitis E Virus and Seoul Hantavirus in Pet Rats, Germany.

Mehl Calvin C, Schilling-Loeffler Katja K, Haake Alexander F H AFH, Sehl-Ewert Julia J et al.

Pet rats represent a reservoir of multiple zoonotic pathogens. We demonstrated that pet rats, previously confirmed to be Seoul orthohantavirus-infected and involved in human infections in Germany, were concurrently infected with rat hepatitis E virus. The high degree of rat hepatitis E virus sequence identity suggests a single incursion event.

PMID 43052263
阅读全文 →
PubMedGut pathogens2026-11-19

Candidate epistatic mutation clusters in occult hepatitis B virus genotype D: a critical narrative review of the evidence gap and a proposed testable framework.

Alkhulaifi Fatima S FS, Al-Qahtani Arwa A AA, Alqassim Emad E, Aljowaie Reem M RM et al.

Hepatitis B virus (HBV) genotype D is the dominant genotype across the Middle East. It forms the background against which diagnostic assays, blood-screening algorithms, and vaccination programmes operate in the region. Occult hepatitis B infection (OBI), the presence of replication-competent HBV DNA in individuals who test negative for hepatitis B surface antigen (HBsAg), remains a persistent challenge for diagnosis, for transfusion and transplant safety, and for the management of immunosuppressed patients. Individual surface-protein escape mutations are well characterised, yet they account only incompletely for the full spectrum of OBI. It is not yet established whether combinations of co-occurring surface mutations interact non-additively, that is epistatically, to influence HBsAg detectability, secretion, or replication in genotype D, whether such combinations are enriched in Middle Eastern populations, or whether they are shaped by HIV or HCV coinfection. The functional and structural data required to answer these questions are largely absent. We critically appraise the available evidence, separate established findings from extrapolation and hypothesis using an explicit grading scheme, and propose a testable bioinformatic and experimental framework to determine whether candidate epistatic clusters contribute to OBI in genotype D. We propose and apply a four-level evidence hierarchy distinguishing co-occurrence, phylogenetically corrected covariation, experimental single-versus-combination comparison, and mechanistic validation. Against this hierarchy, published data on HBsAg mutation clusters in genotype D reach Level 1-2 at most; the decisive Level 3 experiment, site-directed reconstruction of candidate clusters versus their constituent single mutants on a defined genotype D backbone, has not been performed. Genotype-D-specific and Middle-East-specific datasets adequate for cluster-level analysis are limited, direct evidence linking coinfection to selection of mutation clusters is absent, and structural inference remains constrained because recent cryo-EM structures of HBsAg subviral particles do not resolve the 'a' determinant loops at the resolution required to interpret mutation-cluster-level conformational perturbations. Epistasis is a biologically plausible, under-tested mechanism that may help explain why single mutations incompletely account for OBI. It should not be presented as an established driver. We define the sequencing, functional, structural, and clinical studies required to test the hypothesis directly, and we identify the methodological safeguards, particularly phylogenetic correction, that any such effort must adopt.

PMID 43053089
阅读全文 →
PubMedBMC infectious diseases2026-11-19

Comparative analysis of SNPs associated with COVID-19 and chronic liver disease identifies DPP9 as a candidate genetic marker for Long COVID.

da Silva Lucas Lima LL, Maya-Miles Douglas D, Maul Juliana Cardoso JC, Paulo Iolanda Raquel Ferreira IRF et al.

Long COVID is a multisystemic condition characterized by persistent symptoms after acute SARS-CoV-2 infection, whose biological mechanisms are not yet fully understood. Host genetic factors may be associated, and the sharing of genetic architecture with other chronic diseases such as viral hepatitis B and C may aid in understanding this disease. A cross-sectional study was conducted including 150 individuals stratified into two groups: (i) Long COVID and (ii) chronic viral hepatitis B and C. Eighteen single nucleotide polymorphisms (SNPs) previously associated with COVID-19 severity and inflammatory pathways were genotyped using TaqMan® real-time PCR assays. The analyses of genetic association models were performed using multivariate logistic regression adjusted for gender, self-reported skin color, and comorbidities. Mental health scales for assessing depression (Beck), anxiety (Hamilton), fatigue, and post-COVID functional scale were used both to define the syndrome and for subsequent analyses of the genotypic profile probably associated with Long COVID. Among all the SNPs analyzed, rs12610495 (A/G) in the DPP9 gene was the only variant consistently associated with Long COVID. After adjustment for sex, self-reported skin color, and hepatitis status, carriers of the G variant allele demonstrated increased odds of Long COVID under the dominant model (OR = 2.66; 95% CI: 1.08-6.57; p = 0.029) and the overdominant model (OR = 2.96; 95% CI: 1.17-7.52; p = 0.018). The association was more pronounced in women (OR = 3.30; 95% CI: 1.08-10.07). Exploratory analyses of mental and functional outcomes did not reach statistical significance, although a higher frequency of functional limitation and fatigue was observed among carriers of the G allele. This study suggests that DPP9 rs12610495 is associated with Long COVID, previously associated only with severe acute COVID, demonstrating that individuals carrying the rs12610495 G variant allele had higher odds of developing Long COVID. The inclusion of viral hepatitis as a chronic inflammatory condition for comparison contributed to the identification of shared genetic archetypal among diseases, revealing the possible role of DPP9 with Long COVID and highlighting this gene as a relevant target for future validation studies.

PMID 43052846
阅读全文 →
PubMedHepatology international2026-11-19

Longitudinal liver stiffness trajectories and dynamic prediction of liver-related events in chronic hepatitis B.

Jiang Hao H, Chen Yanlin Y, Yu Hongsheng H, Xie Biao B et al.

Serial liver stiffness measurement (LSM) captures evolving disease severity in chronic hepatitis B (CHB), but its longitudinal phenotypes and prognostic value remain uncertain. We aimed to characterize LSM trajectories and develop and externally validate joint models for individualized dynamic prediction of liver-related events (LREs). We analyzed a Beijing development cohort (n=3,927), two external-validation cohorts (n=1,987 and n=747), and a histology-characterized dataset (n=579). Latent class mixed models characterized LSM trajectories, and Bayesian joint models linked repeated LSM measurements with time-to-event outcomes to generate individualized risk estimates. Six LSM phenotypes showed marked prognostic separation, with 9-year LRE incidence ranging from 1.3 to 63.1% (p < 0.001). Despite rapid LSM decline, the moderate-baseline rapid-decline phenotype retained excess hepatocellular carcinoma (HCC) risk versus the persistent low-stable phenotype (adjusted HR 3.46, 95% CI 1.67-7.18). Each 20% increase in updated LSM was associated with LREs (adjusted HR 1.37, 95% CI 1.29-1.46), hepatic decompensation (1.55, 1.43-1.68), and HCC (1.23, 1.14-1.33). For 3-year LRE prediction, the dynamic LSM joint model achieved a mean landmark AUC of 0.833 and generally outperformed joint models based on serial PLT, APRI, and FIB-4, as well as Cox models using the most recent or baseline LSM (median ΔAUC 0.050 [IQR 0.030-0.079] and 0.100 [0.094-0.114], respectively). Adding clinical covariates increased the mean AUC to 0.859, and the final model showed good discrimination in SYSU3 and GEH-SMU (AUCs 0.854 and 0.827, respectively). Serial LSM captures clinically meaningful longitudinal heterogeneity in CHB and supports individualized, dynamically updated risk prediction.

PMID 43052628
阅读全文 →
PubMedJournal of pediatric gastroenterology and nutrition2026-11-19

Atypical inflammatory bowel disease and multi-system inflammation expand the phenotype of inhibitor of nuclear factor kappa B kinase subunit beta gain-of-function variants.

Ashton James J JJ, Selby Mercedes M, Green Zachary Z, Win Lynn K LK et al.

Gain-of-function (GoF) variants in the inhibitor of nuclear factor kappa-B kinase subunit beta (IKK2) protein, encoded by inhibitor of nuclear factor kappa B kinase subunit beta (IKBKB), have previously been reported to cause autoinflammation with a progressive immunodeficiency. Genetic defects have not previously been described in inflammatory bowel disease (IBD), although disruption of highly interacting proteins, such as IKBKG and RELA, are known causes of monogenic IBD. Using whole exome sequencing data, we screened a cohort of over 1250 adult and paediatric onset patients with IBD for deleterious variants (minor allele frequency < 0.0005, Combined Annotation Dependent Depletion [CADD] > 15) in IKBKB. We retrieved in-depth phenotypic data and performed peripheral blood mononuclear cell CD25/CD70 stimulation validation in patients with apparent IKBKB GoF variants. We identified 11 patients with potentially pathogenic variants. Correlation with clinical and immunophenotypic data prioritised a rare, potential gain-of-function, variant in a patient and his affected parent, c.522T>G, p Asp174Glu. The proband had multi-system inflammation and severe atypical inflammatory bowel disease with rectal stricturing. We demonstrated impaired CD25/CD70 T- and B-cell responses in the patient, characteristic of the IKBKB defect, alongside hallmark immunological manifestations of reduced natural killer and B-cell numbers, and perturbed immunoglobulin titres. Treatment with a selective Janus kinase (JAK1)-inhibitor resulted in rapid clinical and biochemical improvement. This study expands the phenotypic manifestation of IKBKB GoF variants to include IBD and demonstrates a biologically plausible targeted treatment. Further functional work is required to elucidate the precise mechanism of bowel inflammation and identify additional patients.

PMID 43053635
阅读全文 →
PubMedBMC gastroenterology2026-11-19

Association of steatotic liver disease with tumour burden and MRI features in hepatocellular carcinoma: a retrospective comparative study.

Guo Yu Y, Gu Yu-Wen YW, Lu Chao C, Cui Wen-Jing WJ et al.

To investigate the associations of steatotic liver disease (SLD) with the clinical characteristics, tumour burden at diagnosis, and major magnetic resonance imaging (MRI) features of hepatocellular carcinoma (HCC). This retrospective study included 130 patients with pathologically confirmed hepatocellular carcinoma who underwent preoperative MRI. Clinical characteristics, tumour burden, and MRI features were compared between patients with and without SLD. Interobserver agreement was assessed using intraclass correlation coefficients and Cohen's κ statistics. The Benjamini-Hochberg procedure was used to control the false discovery rate across multiple comparisons of MRI features. Univariate and multivariable logistic regression analyses were performed to evaluate the association between concurrent SLD and a maximum tumour diameter > 5 cm, with adjustment for age, sex, cirrhosis, alcohol consumption, and hepatitis B surface antigen status in the multivariable model. Patients with concurrent steatotic liver disease (SLD) had a significantly larger maximum tumour diameter than those without SLD (6.30 cm vs. 3.65 cm; P = 0.007) and a higher proportion of tumours with a maximum diameter > 5 cm (60.0% vs. 33.0%; P = 0.011). After adjustment for age, sex, cirrhosis, alcohol consumption, and hepatitis B surface antigen status, SLD remained independently associated with a maximum tumour diameter > 5 cm. An exploratory MRI-defined high tumour burden was also more frequent in the SLD group (73.3% vs. 48.0%; OR = 2.98, 95% CI: 1.21-7.32; P = 0.021). Regarding metabolic characteristics, patients with SLD had a higher prevalence of hypertension and higher γ-glutamyl transferase and triglyceride levels (P < 0.05). None of the conventional MRI features remained statistically significant after false discovery rate correction. Concurrent SLD in patients with HCC may be associated with a greater tumour burden at diagnosis, characterised by a larger tumour diameter and a higher MRI-defined tumour burden, while the major LI-RADS diagnostic features appear to remain unchanged.

PMID 43052771
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多lyophilized hepatitis-B human immunoglobulin